Home Featured Page 283

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

1...282283284...299 Page 283 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

DMT Pricing Guide

Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets...

PT232 – Dr. Ryan Westrum – Who We Are Without Medicine

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery...

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY